OptimAAPP, a smartphone insulin dose calculator for carbohydrate, fat, and protein: A cross‐over, randomised controlled trial in adolescents and adults with type 1 diabetes using multiple daily injection therapy
Authors' conclusion
In adolescents and adults using flexible MDI therapy, OptimAAPP use did not produce glycaemic outcomes that were significantly different from carbohydrate counting. Participant views of OptimAAPP indicate a high level of acceptability. Increasing the size of the food database will likely enhance the user experience.
Study context
- Population
- Adolescents and adults aged 12–50 years with T1D using flexible MDI (≥4 injections/day); mean age 28 ± 12 years, HbA1c 56 ± 10 mmol/mol (7.3 ± 0.9%)ITT analysis
- Participants
- 41 adolescents
- Comparison
- OptimAAPP vs carbohydrate counting for meal insulin dose calculation
- Primary endpoint
- TIR (3.9-10.0 mmol/L) by CGM
- Follow-up
- Weeks 3-4 of each arm
Methodological detailscross-over, free-living
- Cross-over
- Free-living
Primary result
As reported in the abstract
TIR (3.9-10.0 mmol/L)
OptimAAPP
70.5
%
Carbohydrate counting
67.6%
P = 0.102
Further findings
Time above range
P = 0.068
Time below range
P = 0.318
Glucose CV
P = 0.136
Acceptability of OptimAAPP (questionnaire) · end intervention
- Reported OptimAAPP easy to use
- 79%
- Confident in giving recommended doses
- 82%
- Barriers: small food database and time for food entry
Safety
- There was no severe hypoglycaemia
Original publication
OptimAAPP, a smartphone insulin dose calculator for carbohydrate, fat, and protein: A cross‐over, randomised controlled trial in adolescents and adults with type 1 diabetes using multiple daily injection therapy. Diabet Med. Published 9 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →